BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
Markus Berger, Lars Wortmann, Philipp Buchgraber, Ulrich Lücking, Sabine Zitzmann-Kolbe, Antje M. Wengner, Benjamin Bader, Ulf Bömer, Hans Briem, Knut Eis, Hartmut Rehwinkel, Florian Bartels, Dieter Moosmayer, Uwe Eberspächer, Philip Lienau, Stefanie Hammer, Christoph A. Schatz, Qiuwen Wang, Qi Wang, Dominik Mumberg, Carl F. Nising, Gerhard Siemeister
Abstract
oral treatment increased antitumor efficacy, as compared to PSMA-targeted thorium-227 conjugate monotherapy.
Topics & Concepts
ChemistryDNA damageDNADNA repairHomologous recombinationMolecular biologyPharmacologyBiochemistryBiologyDNA Repair MechanismsPARP inhibition in cancer therapyCancer therapeutics and mechanisms